About Medytox
Medytox is a company based in Seoul (South Korea) founded in 2000. The company has 776 employees as of December 31, 2024. Medytox offers products and services including Meditoxin, Innotox, Neuramis, and Coretox. Medytox operates in a competitive market with competitors including Revance Therapeutics, Castle Creek Pharma, Dermavant, Sol-Gel Technologies and Bausch Health, among others.
- Headquarter Seoul, South Korea
- Employees 776 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Medy-Tox Inc.
-
Annual Revenue
$155 M (USD)3.39as on Dec 31, 2024
-
Net Profit
$11.49 M (USD)73.81as on Dec 31, 2024
-
EBITDA
$27.3 M (USD)23.31as on Dec 31, 2024
-
Latest Funding Round
-
Investors
-
Employee Count
776
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Medytox
Medytox is a publicly listed company on the KRX with ticker symbol 086900 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Medytox
Medytox offers a comprehensive portfolio of products and services, including Meditoxin, Innotox, Neuramis, and Coretox.
Botulinum toxin for aesthetic and therapeutic injections.
Liquid formulation for wrinkle treatment and muscle disorders.
Filler for facial volume enhancement and skin rejuvenation.
Toxin product for medical and cosmetic applications.
Funding Insights of Medytox
Investments & Acquisitions by Medytox
Financial Statements - Medytox
Medytox Comparisons
Competitors of Medytox
Medytox operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Revance Therapeutics, Castle Creek Pharma, Dermavant, Sol-Gel Technologies and Bausch Health, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Neurotoxin products for aesthetic and therapeutic skin treatments are developed.
|
|
| domain | founded_year | HQ Location |
Drugs for skin diseases, ENT disorders, and rare diseases such as urea cycle disorders
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for inflammatory skin diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developing topical drug products for the treatment of rosacea, acne and interdigital tinea pedis.
|
|
| domain | founded_year | HQ Location |
Therapeutics for multiple diseases including dermatology and neurology are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics in aesthetics are developed, including botulinum toxin products.
|
Frequently Asked Questions about Medytox
Medytox was founded in 2000.
Medytox is headquartered in Seoul, South Korea.
Chung Hyun-ho is the current CEO of Medytox.
As of Dec 31, 2024, the latest employee count at Medytox is 776.
Annual revenue of Medytox is $155M as on Dec 31, 2024.
Medytox has developed a botulinum toxin for medical aesthetics therapeutic applications. The product, Meditoxin, a botulinum toxin type A marketed under trade names Neuronox, INNOTOX Coretox. These products are used for the treatments of muscle spasticity, foot deformities, Benign essential blepharospasm globular wrinkles. Also developed Hyaluronic Acid Filler (branded as Neuramis Potenfill) to the treatment of facial wrinkles and physical recovery. Also developed medical devices for tissue coagulation injecting applications. The company is also developing the pipeline of biodrugs, medical devices, synthetic drugs health supplements.
Medytox's top competitors include Revance Therapeutics, Dermavant and Bausch Health.
Medytox offers Meditoxin, Innotox, Neuramis, and Coretox.
Yes, Medytox is publicly traded on KRX under the ticker symbol 086900.
The ticker symbol of Medytox is 086900 on KRX.